Quantifying changes in lung tumor volume is important for diagnosis, therapy planning, and evaluation of the response to therapy. Lung tumor volume change is determined by post-processing Computer Tomography (CT) scans of the lung, with good quantitative measurement dependent upon consistency in both scanning procedures and post-processing procedures. The Quantitative Imaging Biomarker Alliance (QIBA) has defined standard procedures for measuring lung tumor volume changes in a document called a Profile, which defines standard working procedures for accurate and reproducible measurement of imaging biomarkers. The Profile is intended to reduce the variation of CT images across scanners and scanning environments. The aim of this study is to measure the variation of tumor volume calculations.
Introduction
Due to the aggressive nature of lung cancer, the response of a patient to a particular treatment must be evaluated quickly and efficiently to get therapy started. X-ray computed tomography is an effective imaging technique for diagnosing lung tumors, planning therapy, and assessing therapy response. In clinical practice, qualitative impressions based on nothing more than visual inspection of the images are frequently sufficient for making patient management decisions. Quantification becomes helpful when tumor masses change slowly over the course of illness. Standards for measurement of objects within images are therefore a necessity to be able to help lung cancer patients. QIBA has led this role, supported by the Radiological Society of North America (RSNA), as "an initiative by researchers, healthcare professionals, and industry to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice." 1 The goal of QIBA is to establish protocols and Profiles (standards documents) that will lead to acceptance of quantitative imaging biomarkers by the imaging community, clinical trial industry, regulatory agencies, and clinicians, as reliable evidence of biology and pathophysiology. A QIBA Profile is a document that describes a specific performance claim and how it can be achieved. It is expected to provide specifications that may be adopted by users and equipment vendors to meet targeted levels of performance. The QIBA Profile for CT Tumor Volume
Change can be found at: http://www.rsna.org/QIBA_Protocols_and_Profiles.aspx.
Determining an appropriate biomarker to measure change in lung tumor size is currently an issue under discussion. Clinicians now utilize 1-dimensional measurements in each slice of CT data containing the tumor. Growth is measured using The Response Evaluation Criteria In Solid Tumors (RECIST), a well-known response criteria based on measurements of maximum axial diameter as a proxy for volume [28, 29] . Limitations of RECIST include the assumption that a change in size volume is reflected in the maximum diameter of the tumor, which is often not the case [20] .
Many investigators have suggested that quantifying whole tumor volumes could solve many of the limitations of RECIST and would have a major impact on patient management [4, 6 and 7, 20, 26-27] . Along with Magnetic Resonance (MR) imaging, functional MR imaging, shear-wave Ultra Sound (US) imaging and Positron Emissions Tomography (PET)/CT, CT volumetry was chosen by QIBA as a biomarker to quantify the effects of novel therapeutic candidates for cancer. The QIBA CT technical committee has constructed a systematic "process map" for qualifying volumetry as a biomarker for response to treatment for a variety of medical conditions, including lung disease [13] .
The performance of volume estimation algorithms is one of several factors that can affect the bias and variance of CT volumetry [24] , in turn affecting whether such measurements can stay within the QIBA Profile guidelines. Current available algorithms include a wide range of methods, requiring different amounts of user input, and different types of software and/or radiological expertise.
Computer algorithms can assist radiologists in areas such as diagnosis, prognosis, and therapy planning, and contribute to the quality and efficacy of treatment. A number of commercial applications are already available in scanners from multiple vendors in clinical practice. One approach to encourage innovation in the development of such algorithms is through the administration of a public "challenge,"
whereby a problem statement is given and solutions are solicited from interested parties that "compete"
at addressing the problem statement. Such challenges in the past included the VOLCANO challenge [1, 19] ) and the BIOCHANGE challenge (NIST) 2 .
The aim of this study is to characterize the performance of multiple algorithms with different levels of automation, for the task of lung tumor volume estimation with CT in a phantom study, and to see whether that performance operates within the 15 % error limits specified by the QIBA Profile.
Phantom studies provide a framework where ground truth is known and can be independently verified.
The study supports the development of QIBA CT Volumetry Profiles and is complementary to additional QIBA efforts that examined inter-reader, inter-scanner, and inter-site variability for this task [25] as well as comparisons between different size metrics [14] . The study also provides a context in which multiple parties have incentives to participate and cooperate, while avoiding direct competition.
Materials and Methods
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Participant procedure
The following outlines the procedure taken by participants in our QIBA 3A challenge study:
 Participants submitted an email to the designated registrar (a non-competing organization, in this case the RSNA) with the signed Participation Agreement and received an anonymous ID back for identification of results.
 Participants downloaded and read the 3A Challenge Protocol on the 3A Wiki 3 .
 Participants downloaded the 3A Challenge data from QI-Bench 4 as described in the Protocol. QIBench provided resources that enabled better use of available data by providing data access methods and an analytical framework for evaluation and optimization.
 Participants took part in 2 different phases of this study: an initial Pilot phase using a subset of the data, followed by the Pivotal, or Test set, utilizing the rest of the data. The Pilot training sets included partially annotated data to set initial parameters for the volume algorithms. The main reason for conducting a Pilot study was to collect enough data to make a good estimate of sample size for the main Pivotal study [30] [31] [32] .
 Participants determined tumor volumes for the initial Pilot set. Then the fully annotated Pilot dataset was made available as a training set and for optimization for the follow-on Pivotal study.
The full truth data was not shared for the Pivotal set. Data for each lesion used in the study included CT scans containing that lesion and one location point for the lesion within those scans.
Location points were defined by a non-participant.
 Participants used the training data to tune the parameters in their individual algorithms. They were then required to use that set of parameters without modification for analysis of the test data set.
(Note: individual participant integrity was relied on to enforce this policy.)
 Participants reported their results in the required formats, signed by the team leader, to the 3A registrar (RSNA). A description of the volumetric algorithm was also required, defining the level of automation used by the algorithm. Fully automated volumetric systems did not require user intervention, whereas semi-automated systems required some degree of user interaction [1] . No participant used manual segmentation. A summary of the degree of automation of algorithms of the participants is given in Table 2 . 
Data description
The studies utilized phantom CT scans previously acquired by the FDA [5] . The CT data was acquired by attaching synthetic lung tumors in a vasculature insert within an anthropomorphic phantom (N1, Kyotokagaku, Kyoto, Japan). Various tumor positions and locations were utilized according to different layouts, shown in Figure 1 . The synthetic tumors varied in size (5, 8, 10, 12, 20 , and 40 mm), shape (spherical, elliptical, lobulated, and spiculated), and in density (-630, -300, -10, +20, and +100 HU).
Fifteen High Resolution Computer Tomography (HRCT) scans containing 97 tumors were used for the pilot phase of the study and 40 HRCT scans containing 408 tumors were used for the pivotal phase.
Acquisitions were made using a 16-detector helical CT scanner (Philips MX800 IDT-16) using an exposure of 100 mAs, 120kVp (peak kilovoltage across the X-ray tube), pitch values of 0.9 and 1.2, 2 slice collimations (16x0.75mm and 16x1.5mm), and a 50 % reconstruction overlap. Two different slice thicknesses, 0.8mm (using 16x0.75mm collimation) and 5mm (using 16x1.5 mm slice collimation),
were considered for image reconstruction along with a detail (B40f) reconstruction kernel. Table 1 summarizes the characteristics of the data set, including which nodules are consistent with the QIBA Profile. Note that only a fraction of the nodules were 12 or 40mm in size, or had density of -300 or 20HU. Those nodules were included for completeness in the Pivotal study only, to stress the system with nodules not seen in the training set.
Data preparation
For each CT series used in the study, the number of nodules chosen varied from 2 to 10. Location points and bounding boxes were given for each nodule. The location points were determined manually by 
Statistical Data Analysis
Statistical analyses were performed on the resulting data, which was sorted with respect to tumor size, shape, density, reconstructed slice thickness, and algorithm automation. For each of these parameters, we calculate both the bias (mean percent error) and variance (standard deviation of mean percent error) in reported tumor volumes. We show bias values for individual parameters instead of absolute mean percent error to show the effect of each parameter on the whether volume measurements were too large or too small. The true size for each synthetic tumor was determined by dividing weight by material density. Mean percent error (mpe) is defined as:
where Vm is measured volume and Vt is true volume. Absolute mean percent error (ampe) is defined as: ampe = (abs(Vm -Vt)/Vt)*100 %.
For each nodule parameter, the mean and SD of the 95 % confidence interval were estimated with bootstrap resampling. Additionally, analyses were conducted for the entire set of nodules, and for the subset of nodules meeting the QIBA Profile (thin slice ≤ 2.5mm, size ≥ 10mm, and solid tumor with excluding density of -630HU). In the Pilot phase, 32 of the 97 met these criteria specified by the QIBA Profile whereas in the pivotal phase, 108 of 408 tumors met these criteria. Finally, two ANOVA analyses were performed to test the effects of all nodule characteristics and CT slice thicknesses on the accuracy of the volume algorithms. The test parameters included the five shapes, five densities, and six sizes of phantom nodules, as well as the two different CT slice thicknesses, listed in Table 1 . First, general
ANOVA was performed to test all factors after Box-Cox transformation of the percent error. For the multiple comparisons within the five shapes and six sizes, p-values were adjusted by the Bonferroni method [16, 17] . Then ANOVA analysis was performed to test the difference between automated and semi-automated algorithms, adjusting for effects of shapes, densities, sizes, and slice thickness.
Analyses were performed using R (version 2.15.1); our scripts are freely available (www.qibench.org). Mean percent error measurements for individual parameters are given in Tables 3, 4 , 5, and 6 and that data are shown visually in radial plots in Figures 3-5 . Table 3 reports mean percent error for all participants and all nodules, with measurements grouped according to the different data parameters (shape, density, slice thickness, and size). Table 4 gives the corresponding standard deviations (SD) for the same groupings. By reporting bias values one can see which nodule types were more likely to under-estimate volumes and which to over-estimate. The average of the mean percent errors is 1.04 % (SD 36.60 %), a low value since it is the average of positive and negative error measurements. The standard deviation of 36.60 % reflects the wide variation in volume estimates. Statistically significant differences were consistently found in the ANOVA analyses across shapes, densities, and sizes, after adjusting for the effect from the different participants (all p<0.001). Mean percent error was the largest for the irregular, 12mm nodules of 20 and -300HU. These nodules were a small fraction of the sample size (2 % combined) and were not represented in the training set. Excluding those nodules from the analysis, mean percent error was largest for the low density (-630HU) nodules. Most commercial algorithms are not designed for such low density nodules, possibly explaining that result. Mean percent error is also larger for the smaller nodules (5mm), which agrees with other findings summarized by Gavrielides et al [24] . Table 3 also shows that mean percent error was reduced for the thin slice series across automated algorithms. It is difficult to make such observations for the semi-automated algorithms, due to the possibility of observer variability, which we do not attempt to measure. The variability (SD values in Table 4 ) was larger for the semi-automated algorithms and increased with decreasing nodule size. The under-sampled 12mm nodules were excluded in the calculation of this variability. Tables 5 and 6 provide the same information contained in Tables 3 and 4 Although we have shown that the overall absolute mean percent error for the nodules compliant with the QIBA Profile is less than 15 %, Table 7 summarizes the fraction of nodules for each individual participant that are less than 15 % (meeting the QIBA requirement) and less than 30 % percent, only for nodules with characteristics meeting the QIBA claim criteria (N=108).
Results
Discussion
Ten different algorithms, including both semi-automated and fully-automated ones, were applied to CT 
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